BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)-Reference-Cited by-同舟云学术

BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)

Published:1999-11 Issue:5 Volume:162 Page:1697-1701
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

SMITH JOSEPH A.,LABASKY RICHARD F.,COCKETT ABRAHAM T.K.,FRACCHIA JOHN A.,MONTIE JAMES E.,ROWLAND RANDALL G.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference5 articles.

1. Smith, J. A., Labasky, R. F., Cockett, A. T. K., Fracchia, J. A., Montie, J. E. and Rowland, R. G.: Bladder Cancer Clinical Guidelines Panel: Report on the Management of Non-Muscle-Invasive Bladder Cancer (Stages Ta, T1 and Tis). Baltimore: American Urological Association, Inc., 1999.

2. A Manual for Assessing Health Practices and Designing Practice Policies: the Explicit Approach;Eddy,1992

3. The confidence profile method: a Bayesian method for assessing health technologies;Eddy;Oper. Res.,1989

4. A Bayesian method for synthesizing evidence: the confidence profile method;Eddy;Int. J. Technol. Assess. Health Care,1990

5. FAST*PRO. Software for Meta-Analysis by the Confidence Profile Method;Eddy,1992

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial;BMJ Open;2024-01

2. [Fever of Unknown Origin in a Patient Administered With Bacillus Calmette-Guérin (BCG) to Treat Urothelial Vesical Carcinoma in Situ];Clinical Management Issues;2023-07-19

3. Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer;European Journal of Nuclear Medicine and Molecular Imaging;2022-11-09

4. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers;Expert Review of Molecular Diagnostics;2022-11-02

5. Cytotoxic Activity of LLO Y406A Is Targeted to the Plasma Membrane of Cancer Urothelial Cells;International Journal of Molecular Sciences;2021-03-24